Jubilant Biosys to begin expansion of its drug discovery services
Category: #health  By Saipriya Iyer  Date: 2019-11-30
  • share
  • Twitter
  • Facebook
  • LinkedIn

Jubilant Biosys to begin expansion of its drug discovery services

Jubilant Biosys, a Jubilant Lifesciences Limited subsidiary based in Bengaluru, recently announced it will be starting with two expansion projects in Bengaluru and Greater Noida.

Jubilant Biosys has started the design and construction of the new and state-of-the-art laboratories for chemistry services on the existing site of the jubilant Greater Noida. It is due to the increase in the demand from the customers for its range of integrated and functional drug discovery services.

The operations are expected to be beginning from the second half of 2020 as the chemistry FTE capacity doubles. Reportedly, the new site is capable of accommodating about 500 Chemistry FTE’s. The site is made to design the highest deliverance of excellent speed, quality and global compliance standards in the process of drug discovery.

According to reliable sources, Jubilant Biosys has secured a plot of 10-acre in Devanahalli Industrial Park in Bengaluru which is located near the International Airport. The company will construct a fully new site for drug discovery services in phases for bigger expansions.

Additionally, Jubilant Biosys has formed a new digitally-based business unit that constitutes AI/ML Data-curation, TrialStat EDC software, Bio-Informatics and discovery focused on the capabilities of AI/ML. The business unit is expected to expand further on the new site as well as deliver enhanced benefits to the company’s customers.

President of Jubilant Biosys and CDMO, Marcel Velterop stated that the company has exhibited excellent scientific execution and given a positive outlook to the drug discovery industry across the globe that has earned major customer confidence. This has also resulted in the largest investment program within Jubilant Biosys since it was incepted first.

Velterop further assured that the company will be offering the customers with enhanced services and capacities along with the capability to deliver a combined IND package with excellent service for functional discovery.

 

Source Credit- https://www.jubilantbiosys.com/wp-content/uploads/2019/11/Press-Release-28-Nov-2019-Jubilant-Biosys-Commences-Major-Capacity-Expansions.pdf



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Sanofi to acquire biotechnology firm Synthorx for $2.5 billion
Sanofi to acquire biotechnology firm Synthorx for $2.5 billion
By Saipriya Iyer

Sanofi, a renowned France based multinational pharmaceutical company, reportedly announced that it would be acquiring California based biotechnology firm, Synthorx, for $2.5 billion. Sanofi offered to purchase all outs...

uniQure updates follow up-data from hemophilia B therapy trials
uniQure updates follow up-data from hemophilia B therapy trials
By Saipriya Iyer

uniQure N.V, a renowned gene therapy firm that advances evolving therapies for all the patients who have severe medical needs, has recently confirmed that it has updated clinical data on three patients who were treated...

Veracyte inks deal with NanoString for nCounter® diagnostic platform
Veracyte inks deal with NanoString for nCounter® diagnostic platform
By Saipriya Iyer

San-Francisco based leading diagnostics company Veracyte has recently announced a definitive agreement with NanoString to acquire global license for the diagnostic use of nCounter® platform. Sources aware of the de...